Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 12 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2017 Filed Mar 1, 2017 00:21 UTC |
JOHNSON R MILTONDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 4,546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-015495 · doc4.xml · nonDerivative · entry 1 JOHNSON R MILTON · CIK 0001216841 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:11 UTC |
YUSPEH ALAN RSVP & Chief Ethics Officer
|
GrantStock Appreciation Right · Derivative | 3,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014545 · doc4.xml · derivative · entry 2 YUSPEH ALAN R · CIK 0001216859 · SVP & Chief Ethics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 17,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 3,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:11 UTC |
YUSPEH ALAN RSVP & Chief Ethics Officer
|
GrantStock Appreciation Right · Derivative | 5,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014545 · doc4.xml · derivative · entry 1 YUSPEH ALAN R · CIK 0001216859 · SVP & Chief Ethics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:10 UTC |
Wyatt Christopher F.SVP & Controller
|
GrantStock Appreciation Right · Derivative | 1,100 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014544 · doc4.xml · derivative · entry 5 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2024-02-05 F4 · balance_after: On February 5, 2014, the reporting person was granted 5,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,100 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:10 UTC |
Wyatt Christopher F.SVP & Controller
|
GrantStock Appreciation Right · Derivative | 1,700 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014544 · doc4.xml · derivative · entry 4 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2023-02-06 F3 · balance_after: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,700 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:10 UTC |
Wyatt Christopher F.SVP & Controller
|
Tax withholdingCommon Stock | 202 | $85.91 | $17,353.82 |
DisclosureSEC source: 0001209191-17-014544 · doc4.xml · nonDerivative · entry 3 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,507 Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:10 UTC |
Wyatt Christopher F.SVP & Controller
|
GrantCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014544 · doc4.xml · nonDerivative · entry 2 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,709 F2 · kind: On February 5, 2014, the reporting person was granted 1,500 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:10 UTC |
Wyatt Christopher F.SVP & Controller
|
GrantCommon Stock | 451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014544 · doc4.xml · nonDerivative · entry 1 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,409 F1 · kind: On February 6, 2013, the reporting person was granted 2,250 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 451 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:09 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
GrantStock Appreciation Right · Derivative | 7,000 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014543 · doc4.xml · derivative · entry 2 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 35,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:09 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
GrantStock Appreciation Right · Derivative | 9,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014543 · doc4.xml · derivative · entry 1 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 45,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 9,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:08 UTC |
Torres Kathryn A.SVP- Employer&Payer Engagement
|
GrantStock Appreciation Right · Derivative | 1,000 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014541 · doc4.xml · derivative · entry 5 Torres Kathryn A. · CIK 0001680636 · SVP- Employer&Payer Engagement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2024-02-05 F4 · balance_after: On February 5, 2014, the reporting person was granted 5,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:08 UTC |
Torres Kathryn A.SVP- Employer&Payer Engagement
|
GrantStock Appreciation Right · Derivative | 1,251 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014541 · doc4.xml · derivative · entry 4 Torres Kathryn A. · CIK 0001680636 · SVP- Employer&Payer Engagement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,251 Underlying: Common Stock · 1,251 shares Expires 2023-02-06 F3 · balance_after: On February 6, 2013, the reporting person was granted 6,250 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,251 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:08 UTC |
Torres Kathryn A.SVP- Employer&Payer Engagement
|
Tax withholdingCommon Stock | 204 | $85.91 | $17,525.64 |
DisclosureSEC source: 0001209191-17-014541 · doc4.xml · nonDerivative · entry 3 Torres Kathryn A. · CIK 0001680636 · SVP- Employer&Payer Engagement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196 Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:08 UTC |
Torres Kathryn A.SVP- Employer&Payer Engagement
|
GrantCommon Stock | 349 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014541 · doc4.xml · nonDerivative · entry 2 Torres Kathryn A. · CIK 0001680636 · SVP- Employer&Payer Engagement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F2 · kind: On February 5, 2014, the reporting person was granted 1,750 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 349 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:08 UTC |
Torres Kathryn A.SVP- Employer&Payer Engagement
|
GrantCommon Stock | 411 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014541 · doc4.xml · nonDerivative · entry 1 Torres Kathryn A. · CIK 0001680636 · SVP- Employer&Payer Engagement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051 F1 · kind: On February 6, 2013, the reporting person was granted 2,050 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 411 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:07 UTC |
STEELE JOHN MSVP - Human Resources
|
GrantStock Appreciation Right · Derivative | 5,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014539 · doc4.xml · derivative · entry 2 STEELE JOHN M · CIK 0001269276 · SVP - Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:07 UTC |
STEELE JOHN MSVP - Human Resources
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014539 · doc4.xml · derivative · entry 1 STEELE JOHN M · CIK 0001269276 · SVP - Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:07 UTC |
STEAKLEY JOSEPH NSVP-Internal Audit Services
|
GrantStock Appreciation Right · Derivative | 3,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014538 · doc4.xml · derivative · entry 2 STEAKLEY JOSEPH N · CIK 0001216853 · SVP-Internal Audit Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 17,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 3,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:07 UTC |
STEAKLEY JOSEPH NSVP-Internal Audit Services
|
GrantStock Appreciation Right · Derivative | 5,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014538 · doc4.xml · derivative · entry 1 STEAKLEY JOSEPH N · CIK 0001216853 · SVP-Internal Audit Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 25,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
Sowell Joseph A IIISVP; Chief Development Officer
|
GrantStock Appreciation Right · Derivative | 5,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014534 · doc4.xml · derivative · entry 2 Sowell Joseph A III · CIK 0001478415 · SVP; Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
Sowell Joseph A IIISVP; Chief Development Officer
|
GrantStock Appreciation Right · Derivative | 9,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014534 · doc4.xml · derivative · entry 1 Sowell Joseph A III · CIK 0001478415 · SVP; Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 45,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 9,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
RUTHERFORD BILL BCFO and EVP
|
GrantStock Appreciation Right · Derivative | 8,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014533 · doc4.xml · derivative · entry 4 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2024-02-05 F3 · balance_after: On February 5, 2014, the reporting person was granted 42,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 8,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
RUTHERFORD BILL BCFO and EVP
|
GrantStock Appreciation Right · Derivative | 1,700 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014533 · doc4.xml · derivative · entry 3 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2023-02-06 F2 · balance_after: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,700 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
RUTHERFORD BILL BCFO and EVP
|
Tax withholdingCommon Stock | 153 | $85.91 | $13,144.23 |
DisclosureSEC source: 0001209191-17-014533 · doc4.xml · nonDerivative · entry 2 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,472 Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:06 UTC |
RUTHERFORD BILL BCFO and EVP
|
GrantCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014533 · doc4.xml · nonDerivative · entry 1 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,625 F1 · kind: On February 6, 2013, the reporting person was granted 2,800 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 560 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:05 UTC |
Perlin Jonathan BPres-Clinical Services & CMO
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014531 · doc4.xml · derivative · entry 2 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Services & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:05 UTC |
Perlin Jonathan BPres-Clinical Services & CMO
|
GrantStock Appreciation Right · Derivative | 11,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014531 · doc4.xml · derivative · entry 1 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Services & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 55,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 11,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:05 UTC |
Paslick P. MartinSVP and CIO
|
GrantStock Appreciation Right · Derivative | 5,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014530 · doc4.xml · derivative · entry 2 Paslick P. Martin · CIK 0001551011 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:05 UTC |
Paslick P. MartinSVP and CIO
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014530 · doc4.xml · derivative · entry 1 Paslick P. Martin · CIK 0001551011 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:04 UTC |
Morrow J WilliamSVP - Finance and Treasurer
|
GrantStock Appreciation Right · Derivative | 1,300 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014529 · doc4.xml · derivative · entry 6 Morrow J William · CIK 0001696543 · SVP - Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2024-02-05 F4 · balance_after: On February 5, 2014, the reporting person was granted 6,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,300 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:04 UTC |
Morrow J WilliamSVP - Finance and Treasurer
|
GrantStock Appreciation Right · Derivative | 1,700 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014529 · doc4.xml · derivative · entry 5 Morrow J William · CIK 0001696543 · SVP - Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2023-02-06 F3 · balance_after: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,700 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:04 UTC |
Morrow J WilliamSVP - Finance and Treasurer
|
Tax withholdingCommon Stock | 201 | $85.91 | $17,267.91 |
DisclosureSEC source: 0001209191-17-014529 · doc4.xml · nonDerivative · entry 3 Morrow J William · CIK 0001696543 · SVP - Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,671.285 Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:04 UTC |
Morrow J WilliamSVP - Finance and Treasurer
|
GrantCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014529 · doc4.xml · nonDerivative · entry 2 Morrow J William · CIK 0001696543 · SVP - Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,872.285 F2 · kind: On February 5, 2014, the reporting person was granted 1,500 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:04 UTC |
Morrow J WilliamSVP - Finance and Treasurer
|
GrantCommon Stock | 451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014529 · doc4.xml · nonDerivative · entry 1 Morrow J William · CIK 0001696543 · SVP - Finance and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,572.285 F1 · kind: On February 6, 2013, the reporting person was granted 2,250 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 451 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:03 UTC |
Morgan Sandra L.SVP-Provider Relations
|
GrantStock Appreciation Right · Derivative | 1,400 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014528 · doc4.xml · derivative · entry 5 Morgan Sandra L. · CIK 0001632836 · SVP-Provider Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires 2024-02-05 F4 · balance_after: On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,400 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:03 UTC |
Morgan Sandra L.SVP-Provider Relations
|
GrantStock Appreciation Right · Derivative | 1,700 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014528 · doc4.xml · derivative · entry 4 Morgan Sandra L. · CIK 0001632836 · SVP-Provider Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2023-02-06 F3 · balance_after: On February 6, 2013, the reporting person was granted 8,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,700 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:03 UTC |
Morgan Sandra L.SVP-Provider Relations
|
Tax withholdingCommon Stock | 358 | $85.91 | $30,755.78 |
DisclosureSEC source: 0001209191-17-014528 · doc4.xml · nonDerivative · entry 3 Morgan Sandra L. · CIK 0001632836 · SVP-Provider Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,419.8654 Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:03 UTC |
Morgan Sandra L.SVP-Provider Relations
|
GrantCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014528 · doc4.xml · nonDerivative · entry 2 Morgan Sandra L. · CIK 0001632836 · SVP-Provider Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,777.8654 F2 · kind: On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 400 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:03 UTC |
Morgan Sandra L.SVP-Provider Relations
|
GrantCommon Stock | 451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-014528 · doc4.xml · nonDerivative · entry 1 Morgan Sandra L. · CIK 0001632836 · SVP-Provider Relations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,377.8654 F1 · kind: On February 6, 2013, the reporting person was granted 2,250 restricted stock units. The restricted stock units are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the restricted stock units subject to such criteria vested, resulting in the vesting of 451 restricted stock units. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:02 UTC |
MOORE A BRUCE JRGroup President - Service Line
|
GrantStock Appreciation Right · Derivative | 5,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014527 · doc4.xml · derivative · entry 2 MOORE A BRUCE JR · CIK 0001216843 · Group President - Service Line 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 27,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:02 UTC |
MOORE A BRUCE JRGroup President - Service Line
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014527 · doc4.xml · derivative · entry 1 MOORE A BRUCE JR · CIK 0001216843 · Group President - Service Line 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:02 UTC |
HAZEN SAMUEL NPresident & COO
|
GrantStock Appreciation Right · Derivative | 16,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014526 · doc4.xml · derivative · entry 2 HAZEN SAMUEL N · CIK 0001216838 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 82,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 16,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:02 UTC |
HAZEN SAMUEL NPresident & COO
|
GrantStock Appreciation Right · Derivative | 19,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014526 · doc4.xml · derivative · entry 1 HAZEN SAMUEL N · CIK 0001216838 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 95,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 19,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:00 UTC |
Hall Charles JGroup President
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014525 · doc4.xml · derivative · entry 2 Hall Charles J · CIK 0001377791 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 25, 2017 00:00 UTC |
Hall Charles JGroup President
|
GrantStock Appreciation Right · Derivative | 11,000 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014525 · doc4.xml · derivative · entry 1 Hall Charles J · CIK 0001377791 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 55,000 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 11,000 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:59 UTC |
Foster Jon MGroup President
|
GrantStock Appreciation Right · Derivative | 7,500 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014524 · doc4.xml · derivative · entry 2 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-02-05 F2 · balance_after: On February 5, 2014, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 7,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:59 UTC |
Foster Jon MGroup President
|
GrantStock Appreciation Right · Derivative | 12,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014524 · doc4.xml · derivative · entry 1 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2023-02-06 F1 · balance_after: On February 6, 2013, the reporting person was granted 62,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 12,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:57 UTC |
Cuffe Michael S.President-Physician Services
|
GrantStock Appreciation Right · Derivative | 2,900 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-17-014523 · doc4.xml · derivative · entry 5 Cuffe Michael S. · CIK 0001632835 · President-Physician Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 Underlying: Common Stock · 2,900 shares Expires 2024-02-05 F4 · balance_after: On February 5, 2014, the reporting person was granted 14,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 2,900 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:57 UTC |
Cuffe Michael S.President-Physician Services
|
GrantStock Appreciation Right · Derivative | 2,500 | $0.00 Strike: $37.18 | $0.00 |
DisclosureSEC source: 0001209191-17-014523 · doc4.xml · derivative · entry 4 Cuffe Michael S. · CIK 0001632835 · President-Physician Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2023-02-06 F3 · balance_after: On February 6, 2013, the reporting person was granted 12,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 2,500 stock appreciation rights. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:57 UTC |
Cuffe Michael S.President-Physician Services
|
Tax withholdingCommon Stock | 411 | $85.91 | $35,309.01 |
DisclosureSEC source: 0001209191-17-014523 · doc4.xml · nonDerivative · entry 3 Cuffe Michael S. · CIK 0001632835 · President-Physician Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,036.0681 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.